HGS Calls For Confidence In Slow, Steady Ramp-Up For Benlysta
This article was originally published in The Pink Sheet Daily
In the fourth quarter, the new SLE drug continued its slow sales growth – HGS said rheumatologists are still largely in trial mode, testing the drug in a few patients and gaining confidence in its benefits.
You may also be interested in...
With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.
GSK plans to take its $13 per share offer straight to Human Genome Sciences shareholders after being turned down by the company last month.
Human Genome Sciences says the long-term blockbuster opportunity in Benlysta and the potential of its pipeline products are under-valued by GlaxoSmithKline’s takeover offer. Management at GSK, however, plays down any talk of increasing its bid.